Atomo Diagnostics Ltd. (AU:AT1) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Atomo Diagnostics Ltd. has welcomed the Australian Federal Government’s budget allocation of $43.9 million towards expanding HIV Self-Testing, aiming to eliminate HIV transmission by 2030. The company, which supplies the only ARTG-listed HIV Self-Test, expects a significant portion of the funds to support the procurement of their tests as part of the national HIV self-test mail-out program and vending machine pilot expansion. This funding follows the recognition of the importance of self-testing in meeting national HIV targets, and Atomo is committed to ensuring widespread access to these tests.
For further insights into AU:AT1 stock, check out TipRanks’ Stock Analysis page.